Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone

Pharmacology Biochemistry and Behavior

Volumn 69, Issue 3-4, 2001, Pages 535-542

  Mansbach, Robert S ^a   Carver, Jody ^a   Zorn, Stevin H ^a  

^a PFIZER INC   (United States)

Author keywords

Antipsychotics clozapine; Haloperidol; Prepulse inhibition; Startle; Ziprasidone

Indexed keywords

APOMORPHINE; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; SEROTONIN 5 RECEPTOR; ZIPRASIDONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EXTRAPYRAMIDAL SYNDROME; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOIDISM; SCHIZOPHRENIA; STARTLE REFLEX;

ACOUSTIC STIMULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; KETAMINE; MALE; NEURAL INHIBITION; PIPERAZINES; RATS; RATS, WISTAR; STARTLE REACTION; THIAZOLES;

RATTUS NORVEGICUS;

EID: 0034864981     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(01)00561-5     Document Type: Article

References (46)

1. Neurophysiological studies of sensory gating in rats: Effects of amphetamine, phencyclidine, and haloperidol
2. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
3. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine
4. Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist
5. Alpha-1-adrenergic receptors mediate sensorimotor gating deficits produced by intracerebral dizocilpine administration in rats
6. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response
7. Reversal of isolation rearing-induced deficits in prepulse inhibition by seroquel and olanzapine
8. Prestimulus effects on human startle reflex in normals and schizophrenics
9. Disruption in prepulse inhibition after alpha-1 adrenoceptor stimulation in rats
10. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
11. Knockout mice reveal opposite roles for serotonin 1A and 1B receptors in prepulse inhibition
12. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia
13. The effects of subchronic haloperidol on intact and dizocilpine-disrupted sensorimotor gating
14. Elementary neuronal dysfunctions in schizophrenia
15. Effects of LU-111995 in three models of disrupted prepulse inhibition in rats
16. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder
17. The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801
18. The atypical antipsychotic, remoxipride, blocks phencyclidine-induced disruption of prepulse inhibition in the rat
19. Time course of antipsychotic effects of neuroleptic drugs
20. Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle
21. Drug treatment of the negative symptoms of schizophrenia
22. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
23. Study of a new schizophrenomimetic drug-sernyl
24. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat
25. Parametric determinants in pre-stimulus modification of acoustic startle: Interaction with ketamine
26. Dopaminergic stimulation disrupts sensorimotor gating in the rat
27. Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition
28. Disorders of attention and perception in early schizophrenia
29. Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia
30. Dimensions of outcome with clozapine
31. The pharmacology of olanzapine and other new antipsychotic drugs
32. Chronic treatment with haloperidol diminishes the phencyclidine-induced sensorimotor gating deficit in rats
33. 5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in rat prefrontal cortex
34. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
35. DOI disruption of prepulse inhibition in the rat is mediated by 5-HT2A and not by 5-HT2C receptors
36. Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: Inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation
37. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia
38. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients
39. Seroquel restores sensorimotor gating in phencyclidine-treated rats
40. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats
41. Ziprasidone: A novel antipsychotic with unique pharmacology therapeutic potential
42. M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats
43. Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain
44. Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats
45. Pharmacological and neurochemical studies with the new antipsychotic ziprasidone